PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.
Analyze analyst forecasts for the company and compare them with competitors.
124.50M
Better than MCRB's estimated revenue of 0.
-24.90M
Worse than MCRB's estimated ebitda of 0.
0.56
Better than MCRB's estimated eps of -9.75.
16.74M
Better than MCRB's estimated net income of -1.52B.
-24.90M
Worse than MCRB's estimated ebit of 0.
4.61B
Worse than MCRB's estimated sg&a expense of 0.
Analyze DCF forecasts for the company and compare them with competitors.
1.03M
Worse than MCRB's revenue of 7.13M.
-9.97%
Better than MCRB's revenue growth rate of -95.08%.
-33.41M
Better than MCRB's ebitda of -237.51M.
-3243.20%
Better than MCRB's ebitda margin of -3332.04%.
-34.10M
Better than MCRB's ebit of -249.36M.
-3311.07%
Better than MCRB's ebit margin of -3498.33%.
699.00K
Better than MCRB's depreciation of 11.85M.
108.91M
Worse than MCRB's total cash of 181.34M.
10573.79%
Better than MCRB's cash as percentage of revenue of 2544.07%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
10.13M
Better than MCRB's accounts payable of 17.44M.
983.50%
Worse than MCRB's payables as percentage of revenue of 244.67%.
-366.00K
Worse than MCRB's capital expenditure of -9.82M.
-35.53%
Worse than MCRB's capex as percentage of revenue of -137.78%.
4.99%
Better than MCRB's weighted average cost of capital (wacc) of 8.80%.
5.02%
Better than MCRB's cost of equity of 13.94%.
4.08%
Better than MCRB's cost of debt of 6.16%.
-0.23
Better than MCRB's beta of 2.05.
30.07M
Better than MCRB's diluted shares outstanding of 128.00M.
1.57M
Better than MCRB's total debt of 213.94M.
49.31M
Worse than MCRB's total equity of 110.08M.
50.89M
Worse than MCRB's total capital of 324.02M.
3.09%
Better than MCRB's debt weighting of 66.03%.
96.91%
Better than MCRB's equity weighting of 33.97%.
-32.98M
Better than MCRB's ebiat of -253.02M.
-28.05M
Better than MCRB's unlevered free cash flow of -247.28M.
2.00%
Equal to MCRB's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Better than MCRB's net debt of 85.97M.
71.33M
Better than MCRB's equity value of -3.24B.
2.37
Better than MCRB's equity value per share of -25.33.